X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
The global clinical trial will assess the efficacy, safety, and pharmacokinetics (PK) profile of CBP-201, was designed to enroll 220 subjects and is being conducted at 60 sites across the US, China, Australia, and New Zealand.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OQL011
Therapeutic Area: Dermatology Product Name: OQL011
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Shiyu Capital
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 31, 2021
Details:
Proceeds from the financing will support the Phase II clinical trial of the company's leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Renaissance Capital
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 26, 2021
Details:
Connect's lead candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD) and asthma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMG-20
Therapeutic Area: Dermatology Product Name: IMG-20
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Vertex Ventures
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 09, 2020
Details:
The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. IMG-20, Inmagene’s most advanced drug candidate, is about to enter the global registration trials for multiple indications.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
